Treatment-resistant depression
Treatment-resistant depression is a form of major depression that has not improved enough after adequate trials of at least two antidepressants, a common working definition. The label describes response to past care, not a person's character, a single cause, or proof that no options remain.
- Common definition
- Inadequate response to two antidepressants
- Not one cause
- Many factors may contribute
- Psilocybin status
- Research remains ongoing
- U.S. legality
- Federally Schedule I
What does treatment-resistant depression mean?
Treatment-resistant depression, often shortened to TRD, is a clinical term for major depression that has not improved enough after treatment attempts. A commonly used definition looks for inadequate response to at least two different antidepressants, each taken at an appropriate dose and for a sufficient period. There is no single definition used everywhere, however, so researchers and clinicians may apply the label somewhat differently.
The word resistant can sound final, but it does not mean that a person cannot improve or that every possible option has been tried. It describes how symptoms responded to certain past treatments. A person's experience, treatment history, and needs are more complex than a label, and the term does not identify one cause or biological process.
- 1Review symptoms
Discuss the pattern, duration, and impact of depressive symptoms.
- 2Check treatment history
Review medications tried, how long they were used, and the response.
- 3Consider contributors
Look for other health conditions, side effects, and practical barriers.
- 4Clarify the picture
Reassess the diagnosis and whether other factors may affect symptoms.
- 5Discuss options
Consider next steps with a qualified health professional.
How does treatment-resistant depression develop?
TRD is not a separate condition that forms in the way a mushroom or fungus grows. It is a description applied after reviewing a person's depression and response to care. Symptoms may continue for different reasons, and sometimes an apparent lack of response reflects a poor fit between the person and a treatment, rather than a single underlying mechanism.
Clinicians may review the timing and severity of symptoms, past treatment details, and other health or life factors. Co-occurring mental or physical conditions, side effects, difficulty staying with a treatment, and practical barriers to care can all complicate the picture. These are possibilities to consider, not assumptions about any individual, and a TRD label alone cannot explain why symptoms persist.
Common definitions involve inadequate response to at least two antidepressants.
The label describes response, not a single explanation.
Psilocybin studies are ongoing; it is not an approved TRD treatment.
Editorial placement to help compare; not a measurement.
Why is psilocybin research connected to treatment-resistant depression?
Psilocybin is a naturally occurring compound in some fungi. Researchers have studied it in controlled settings for depression, including cases described as treatment-resistant. Early studies have reported changes in symptoms for some participants, but results from research do not establish that psilocybin is a proven or approved treatment for TRD. Larger studies and further follow-up are needed to clarify benefits, limits, and risks.
One research question is how psilocybin's effects on serotonin signaling, including activity involving the 5-HT2A receptor, relate to changes in mood or perception. That is an area of study, not a settled explanation for depression or a guarantee of benefit. Clinical research protocols may include screening, preparation, and professional support, which are distinct from unsupervised use or products sold as mushrooms.
| Treatment-resistant depression | Major depression | Psilocybin research | |
|---|---|---|---|
| What it means | Depression with inadequate treatment response | A condition affecting mood and daily life | Studies of a compound and its effects |
| How defined | Often after two antidepressant trials | By symptoms and clinical assessment | By each study's research criteria |
| What it describes | Response to past care | A mental health condition | An area under investigation |
| U.S. status | A clinical label | A health condition | Not an FDA-approved TRD treatment |
Where do people encounter treatment-resistant depression?
People may encounter the term in mental health care, research papers, or news about new approaches to depression. In the United States, psilocybin remains federally classified as a Schedule I substance. State-regulated supervised access exists through programs in Oregon and Colorado; New Mexico's medical program is being set up. State programs do not make psilocybin federally legal or mean it is an FDA-approved treatment for depression.
Research participation is different from access through a state program, and rules vary by location. A headline about a study or a supervised program should not be taken as proof that a substance is safe or effective for everyone. Psilocybin experiences can be intense and unpredictable, so research settings use safeguards. This glossary is general education, not personal medical or legal advice.
- 2016
An open-label study of psilocybin for treatment-resistant depression was published.
- 2018
The FDA granted breakthrough therapy designation to a psilocybin therapy program for TRD.
- 2021
A phase 2b trial of psilocybin for treatment-resistant depression was published.
What are common misconceptions about treatment-resistant depression?
A common misconception is that resistant means hopeless. It does not: the label records an inadequate response to particular treatment attempts, not a prediction that nothing can help. Another is that TRD always has one cause. Depression and its course vary, and the label does not reveal whether biological, psychological, social, or health-related factors are involved.
For mushroom readers, it is also important not to confuse a research compound with an ordinary mushroom product. Psilocybin and its related compound psilocin are different from many other mushroom constituents, and a mushroom product is not interchangeable with a controlled research protocol. Learn about fungi and psychedelics as separate topics; do not assume that mushroom supplements or wild species are appropriate for depression.
Common questions about Treatment-resistant depression
What counts as treatment-resistant depression?
A common working definition is major depression that has not improved enough after at least two different antidepressants taken at an adequate dose and for an adequate time. Definitions can vary among clinicians and studies, so the term is not applied identically in every setting.
Does treatment-resistant depression mean nothing will help?
No. The term describes an inadequate response to certain past treatment attempts; it does not predict that a person will never improve. It also does not explain why symptoms persist. A qualified health professional can assess an individual's history and discuss appropriate options.
Is psilocybin approved for treatment-resistant depression in the U.S.?
No. Psilocybin is federally Schedule I in the United States and is not an FDA-approved treatment for TRD. State-regulated supervised access exists in Oregon and Colorado, and New Mexico's medical program is being set up. State programs are not the same as federal approval.
What does research say about TRD and psilocybin?
Early clinical studies have explored psilocybin for depression, including treatment-resistant depression, and reported possible symptom changes in some participants. This remains an area of research, not proof of an established treatment. Study results do not show that psilocybin is safe or effective for every person.
Related terms
Explore on Pscilly
Sources and further reading
Written by the Pscilly editorial team and reviewed November 2026. Educational content only, not medical or legal advice. Pscilly does not sell psilocybin. Never eat a wild mushroom without expert identification.